BICILLIN C-R 900/300 Rx
Generic Name and Formulations:
Penicillin G benzathine 900,000 units, penicillin G procaine 300,000 units; per syringe; susp for deep IM inj; contains parabens.
Indications for BICILLIN C-R 900/300:
Susceptible moderately severe infections including respiratory, skin and soft tissue, erysipelas, scarlet fever, otitis media.
Use other strengths.
Give by deep IM inj into upper, outer buttock or anterolateral thigh; for younger children, midlateral thigh may be preferred. Group A strep: one inj of 900/300 once. Pneumococcal: one inj of 900/300 every 2–3 days until afebrile for 48 hours.
Not for IV use. Do not admix with other IV solutions. Reports of inadvertent IV administration has been associated with cardiorespiratory arrest and death.
Not for IV use; do not inject into or near an artery or nerve. History of cephalosporin or significant allergies. Asthma. Increased risk of methemoglobinemia in G6PD deficiency, congenital/idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants <6mos; monitor and discontinue if occurs. Monitor renal and hematopoietic function in prolonged use. Discontinue if superinfection develops. Pregnancy. Nursing mothers.
Do not admix with other intravenous solutions. Antagonized by concomitant tetracycline; avoid. Potentiated by probenecid. Increased risk of methemoglobinemia with concomitant local anesthetics, acetaminophen, sulfonamides, nitrates, phenytoin, phenobarbital; see full labeling.
Rash, drug fever, serum sickness, anaphylaxis, blood dyscrasias, neuropathy, nephropathy, inj site reactions, methemoglobinemia, C. difficile-associated diarrhea.
C-R disposable syringe 600,000 units/mL (2mL)—10 (w. 1 inch or 1.25 inch needles); C-R 900/300 disposable syringe 1.2 million units (2mL)—10 (w. 1 inch needle)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer